The FDA granted approval for Eli Lilly’s revised dosing regimen of Alzheimer’s drug Kisunla to reduce the risk of brain swelling, addressing safety concerns that had limited its adoption. Separately, Exact Sciences announced its Oncodetect molecular residual disease test received CMS coverage for monitoring colorectal cancer patients post-surgery, enabling earlier detection of recurrence. The assay detects circulating tumor DNA variants with high sensitivity and is covered for serial use in stages II-IV colorectal cancer. These approvals improve clinical management options in their respective fields and may impact patient monitoring and treatment strategies.